On March 18, 2017, Stan Yarbro was removed as a director ("Director") of Calmare Therapeutics, Inc. (the "Company") by a majority vote of the Board of Directors pursuant to a duly called special meeting of the Board of Directors. Per Article II, Section 2.11 of the Bylaws of the Company, except as may otherwise be provided by the Delaware General Corporation Law, any director of the Corporation may be removed by a vote of a majority of the Board of Directors in the event such Director has violated his or her fiduciary duties to the Corporation or has violated the Corporate Code of Conduct as then in effect.
